Chinook Acquires Global Rights to Develop Atrasentan for Alport, Other Kidney Diseases
Chinook Therapeutics acquired the global rights for the development and commercialization of AbbVie‘s atrasentan, an investigational compound for the treatment of people with primary glomerular kidney disease, including patients with Alport syndrome. Chinook, a Canadian biotech focused on medicines for kidney diseases, expects to launch…